Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

176 results about "Photoreceptor cell" patented technology

A photoreceptor cell is a specialized type of neuroepithelial cell found in the retina that is capable of visual phototransduction. The great biological importance of photoreceptors is that they convert light (visible electromagnetic radiation) into signals that can stimulate biological processes. To be more specific, photoreceptor proteins in the cell absorb photons, triggering a change in the cell's membrane potential.

Bio-synthetic photostimulators and methods of use

Cells are rendered sensitive to stimulation by introducing into a non-photoreceptor cell nucleic acid sequences encoding at least an opsin gene product, an arrestin gene product, and the alpha subunit of the heterotrimeric G protein of the Gq family. The introduced sequences are expressed by the cell to yield at least the opsin gene product, the arrestin gene product, and the alpha subunit of the heterotrimeric G protein of the Gq family. Retinal or a derivative thereof capable of bonding with the opsin gene product to form a rhodopsin is provided to the cell. The cell is then irradiated with light having a wavelength capable of converting the rhodopsin to metarhodopsin. The conversion of rhodopsin to metarhodopsin triggers a cascade of intracellular responses within the cell resulting in an increased intracellular concentration of IP3 and calcium ions.
Owner:SLOAN KETTERING INST FOR CANCER RES

Management of ophthalmologic disorders, including macular degeneration

InactiveUS20060069078A1A2E production can be reducedInhibit bindingBiocideSenses disorderDiseaseRod Photoreceptor Cells
A drug may be used in the preparation of a medicament for the treatment or prevention of an ophthalmologic disorder, wherein the drug inihibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE

Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids

Nucleic acid vectors encoding light-gated cation-selective membrane channels, in particular channelrhodopsin-2 (Chop2), converted inner retinal neurons to photosensitive cells in photoreceptor-degenerated retina in an animal model. Such treatment restored visual perception and various aspects of vision. A method of restoring light sensitivity to a retina of a subject suffering from vision loss due to photoreceptor degeneration, as in retinitis pigmentosa or macular degeneration, is provided. The method comprises delivering to the subject by intravitreal or subretinal injection, the above nucleic acid vector which comprises an open reading frame encoding a rhodopsin, to which is operatively linked a promoter and transcriptional regulatory sequences, so that the nucleic acid is expressed in inner retinal neurons. These cells, normally light-insensitive, are converted to a light-sensitive state and transmit visual information to the brain, compensating for the loss, and leading to restoration of various visual capabilities.
Owner:WAYNE STATE UNIV +1

System for maintaining normal health of retinal cells and promoting regeneration of retinal cells

InactiveUS20070093877A1Stay healthyPromoting regeneration and functionElectrotherapyMedicineElectrical stimulations
Disclosed is a system for maintaining normal health of photoreceptor cells and promoting regeneration of photoreceptor cells, and methods thereof. The system comprises: an implant capable of being implanted in a region in proximity to retina of an eye; and an electrical stimulation unit disposed in a region around the eye. The electrical stimulation unit induces an electrical current in the implant for electrical stimulation of the retina of the eye, thereby maintaining normal health of photoreceptor cells and promoting regeneration of photoreceptor cells in the retina.
Owner:BEECHAM MICHAEL C +1

Brimonidine compositions and methods for retinal degeneration

The present study demonstrates that brimonidine tartrate, an alpha-2 adrenergic receptor agonist, can prevent photoreceptor cell degeneration and the associated Muller cell degenerative signs in an in vitro model of retinal degeneration and retinal detachment (separation of the neuroretina from the retinal pigment epithelium). Similar to control conditions, brimonidine allowed for the formation of highly structured photoreceptor outer segments, prevented the expression of stress markers in Müller cells and preserved the expression patterns of Muller cell markers of proper cell-cell contact and differentiation. Ultrastructural studies also indicated that brimonidine favored the formation of cell-cell junctions between photoreceptor cells and Müller cells, indicating that this phenomenon is associated with the exertion of the neuroprotective effect. The results suggest that brimonidine compounds may be utilized as an effective therapeutic agent for early and late onset retinal degenerations caused by defects in photoreceptor cells, Müller cells or both, and as an adjuvant to therapeutic success in retinal detachment surgery or macular translocation surgery for age-related macular degeneration.
Owner:UNIV OF TENNESSEE RES FOUND

Functional abiotic nanosystems

ActiveUS20090088843A1Imparting photoreactivityPowder deliveryEnergy modified materialsCell membraneNerve cells
The invention relates to imparting photoreactivity to target cells, e.g., retinal cells, by introducing photoresponsive functional abiotic nanosystems (FANs), nanometer-scale semiconductor / metal or semiconductor / semiconductor hetero-junctions that in this case include a photovoltaic effect. The invention further provides methods of making and using FANs, where the hetero-junctions bear surface functionalization that localizes them in cell membranes. Illumination of these hetero-junctions incorporated in cell membranes generates photovoltages that depolarize the membranes, such as those of nerve cells, in which FANs photogenerate action potentials. Incorporating FANs into the cells of a retina with damaged photoreceptor cells reintroduces photoresponsiveness to the retina, so that light creates action potentials that the brain interprets as sight.
Owner:UNIV OF SOUTHERN CALIFORNIA

Human visual perception simulation-based self-adaptive low-illumination image enhancement method

The invention provides a human visual perception simulation-based self-adaptive low-illumination image enhancement method. The method is put forwards based on characteristics of low brightness and low contrast of a low-illumination color image and through researching an automatic adjustment process of pupils and photoreceptor cells for an environment. The method includes the following steps that: the adjustment process of the pupils for light is simulated, and the total brightness level of the image is improved; and the self-adaptive adjustment and control ability of eye vision for a low-illumination environment is simulated, and a nonlinear mapping model is designed to simulate the adjustment process of rod cells and cone cells, so that a bright and dark self-adaptation function can be obtained, and a bright and dark information fusing function is determined according to illumination distribution, and global self-adaptive adjustment is performed on brightness components; and the local contrast of the enhanced brightness image will be decreased, so that local self-adaptive contrast enforcement is performed on the image through adopting an exponential function; and finally, and color restoration is performed on the enhanced image. With the human visual perception simulation-based self-adaptive low-illumination image enhancement method of the invention adopted, the brightness, local contrast and detail information of the low-illumination color image can be effectively improved, and especially, the method has obvious effects in dark area and highlight area enhancement.
Owner:SOUTHWEAT UNIV OF SCI & TECH

Artificial biocompatible material as a support for cells in a retinal implant

A retinal implant is provided that uses an artificial biocompatible material as a support material on which retinal pigment epithelial cells, iris pigment epithelial cells, and / or stem cells can be deposited either in situ or in vivo. The support material has a surface topology that is rough to promote cell adhesion, has surface pits to allow pigment cells to grow into, and has pores to allow for proper diffusion of materials. The support material serves as a substrate for cell growth and as a patch for damaged basement membrane (Bruch's membrane). This cell-coated membrane or pigment cell-enriched membrane is surgically positioned in the sub-retinal space to rescue or restore photoreceptor cell function that may be damaged or threatened by degenerative diseases of the eye, such as age-related macular degeneration.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase) - inhibitory peptide, and use of the peptide

Intravitreal administration of a JNK-inhibitory peptide less than 150 amino acids in length, containing at least one D-amino acid, and having (a) a JNK-inhibitory sequence of at least any of SEQ ID NO: 1 and SEQ ID NO: 2, and (b) a transport sequence of at least any of SEQ ID NO: 3 and SEQ ID NO: 4 suppressed spermidine-induced retinal pigment epithelial damage, tunicamycin-induced photoreceptor cell damage, and laser-induced choroidal neovascularization. Thus, the JNK-inhibitory peptide of the present invention is useful for prophylaxis or therapy of a retinal disease. By the use of this JNK-inhibitory peptide, a drug and a method are provided which are capable of preventing or treating a retinal disease even by topical administration to the eye, and use of the JKN-inhibitory peptide for manufacturing the drug is also provided.
Owner:SANTEN PHARMA CO LTD

Method for augmenting vision in persons suffering from photoreceptor cell degeneration

The invention provides compositions and methods of treating subjects afflicted with a photoreceptor disorder. Methods for treating a subject suffering from a disorder characterized by photoreceptor cell degeneration are provided, wherein a gene encoding a photosensitive protein is introduced into a retinal cell of a subject. In one aspect of the invention, the retinal cells which receive the photosensitive protein include non-photoreceptor cells such as horizontal cells, amacrine cells, bipolar cells, and ganglion cells.
Owner:THE GENERAL HOSPITAL CORP

Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells

Provided are methods and compositions for maintaining the viability of photoreceptor cells and / or retinal pigment epithelial cells in a subject with an ocular disorder including, for example, age-related macular degeneration (AMD) (e.g., dry or neovascular AMD), retinitis pigmentosa (RP), or a retinal detachment. The viability of the photoreceptor cells and / or the retinal pigment epithelial cells can be preserved by administering a necrosis inhibitor either alone or in combination with an apoptosis inhibitor to a subject having an eye with the ocular condition. The compositions, when administered, maintain the viability of the cells, thereby minimizing the loss of vision or visual function associated with the ocular disorder.
Owner:VAVVAS DEMETRIOS +3

Labeling composition for intraocular tissue, labeling method of intraocular tissue, and screening method

The invention provides a labeling composition for an intraocular tissue of a living individual, which specifically labels the intraocular tissue without need of an invasive operation such as exposure of an ocular tissue or injection of a staining agent into the ocular tissue or a nerve tissue linking to the ocular tissue, a method of noninvasively labeling an intraocular tissue of a living individual, and a screening method using the labeling composition for the intraocular tissues. The composition contains a compound capable of labeling at least a photoreceptor cell layer of a retina, wherein the compound is a staining compound having a particular structure as a partial structure thereof.
Owner:CANON KK

Low oxygen culture conditions for maintaining retinal progenitor cell multipotency

The present invention relates to methods for culturing human retinal progenitor cells under low oxygen conditions to allow the cells to retain the ability to differentiate into photoreceptors following transplantation. The described methods provide cells that can treat a number of ocular diseases, including retinitis pigmentosa and age-related macular degeneration.
Owner:THE SCHEPENS EYE RES INST

Universal markers of transgenesis

The invention relates to methods, cells and nucleic acids for making transgenic animals. The methods generally comprise introducing into a genome of an animal a genetic construct comprising a transcriptional regulatory element operably linked to a heterologous marker gene encoding a marker, wherein the element drives expression of the marker across genera transgenic in the construct sufficient to visually detect the marker in photoreceptive cells or organs, and selecting for transgenesis by visually detecting the marker in a photoreceptive cell or organ of the animal.
Owner:WIMMER ERNST A +2

Optical pickup device

First order diffraction lights reflected on a first signal face for reproducing an optical disc and further deflected by a spatial divide element converge to spots 21a to 21d on photo acceptance cells 9A to 9D of a photodetector 9, while diffraction lights reflected on the first signal face and further diffracted by other orders of diffraction except plus first-order and diffraction lights reflected on a second signal face become crosstalk lights. Therefore, an optical pickup device is adapted so that minus (−) first-order diffraction lights 23a to 23d from the first signal face and the spots 21a to 21d of the first order diffraction light from the second signal face are not radiated on the photo acceptance cells 9A to 9D.
Owner:VICTOR CO OF JAPAN LTD

Compositions for inducing differentiation into retinal cells from retinal progenitor cells or inducing proliferation of retinal cells comprising wnt signaling pathway activators

ActiveUS20110223660A1Readily transplanted into degenerated or injured retinasHigh yieldCulture processNervous system cellsGene transferIn vivo
Disclosed is a composition for inducing the proliferation of retinal cells or the differentiation of retinal progenitor cells into retinal cells. The composition, similar to in vivo conditions for development during embryogenesis, induces stem cells to differentiate into a multitude of photoreceptor cells at high yield within a short period of time, without an additional gene transfer. In addition, the differentiated photoreceptor cells are useful in cellular therapy because they, when transplanted into degenerated or injured retinas, can be engrafted and fused within the retinas to prevent or cure retinal degeneration.
Owner:CLAVISTHERAPEUTICS INC

Methods and compositions for preserving the viability of photoreceptor cells

Provided are methods and compositions for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a neuroprotective agent, for example, a substance capable of suppressing endogenous calcineurin or constitutively active calcineurin, inhibiting cleavage of calcineurin to constitutively active calcineurin, and / or directly or indirectly antagonizing calcineurin or constitutively active calcineurin (and combinations thereof), to a mammal having an eye with retinal detachment. The neuroprotective agent maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid. The treatment minimizes the loss of vision, which otherwise may occur as a result of retinal detachment.
Owner:MASSACHUSETTS EYE & EAR INFARY

Image Processing Apparatus and Image Processing Method

An image processing apparatus includes an alignment unit configured to align a first fundus oculi image that is an aberration-corrected image of an eye being examined and a second fundus oculi image having a larger view angle and a lower resolution than the first fundus oculi image, by using a third fundus oculi image having a smaller view angle and a higher resolution than the second fundus oculi image; a distance acquisition unit configured to acquire a distance from a macula lutea of the eye being examined to a certain position in the first fundus oculi image aligned by the alignment unit; and an evaluation unit configured to evaluate the state of the eye being examined from the distance and information concerning photoreceptor cells included in the first fundus oculi image.
Owner:CANON KK

Construction method for model of animals with retinitis pigmentosa diseases and application

The invention discloses a construction method for a model of animals with retinitis pigmentosa diseases and application and relates to the technical field of medical engineering. According to the construction method for the model of the animals with the retinitis pigmentosa diseases, Hkdcl gene sequences on genomes of target animals are knocked out, the model of the animals with the retinitis pigmentosa diseases is obtained, the model of the animals presents typical characteristics, such as retina function damage and gradualness apoptosis of photoreceptor cells, of retinitis pigmentosa, the model of the animals can be applied to research of the retinitis pigmentosa diseases and medicine for screening treatment of the retinitis pigmentosa diseases, and the method has wide application prospects.
Owner:SICHUAN PROVINCIAL PEOPLES HOSPITAL

Methods to extend vision to infrared wavelengths

In a method for visualizing an object under conditions of low ambient light, the object to be visualized is exposed to incident electromagnetic radiation having a wavelength greater than what can normally be seen by the naked eye. Light reflected from the object is then perceived with an enhanced eye. The enhanced eye contains an up-conversion material optically coupled to the photoreceptors. Up-conversion materials absorb in the infrared and luminesce in the visible. Particles containing such materials are delivered to the eye where they are optically coupled to the retina or photoreceptor cells and nearby tissues. There they provide in-situ up-conversion of infrared frequencies (from about 700 to about 11,000 nm) to the otherwise unaided eye.
Owner:BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIV

Application of GMFB (glia maturation factor beta), GMFB disrupter and application of GMFB disrupter

ActiveCN105154527AElevated GMFB contentDecreased glutamine synthaseMetabolism disorderGenetic material ingredientsDiabetes retinopathyDisease course
The invention relates to application of GMFB (glia maturation factor beta) as a biomarker for early diagnosis of diabetic retinopathy and for diabetes progression, application of GMFB as a therapeutic target of diabetic retinopathy, a GMFB disrupter and application of the GMFB disrupter. Compared with the prior art, the invention proves that the GMFB content in vitreous body is significantly improved in early period of diabetes in rats of STZ-induced I type diabetes (TIDM). The invention is the first to prove that GMFB content gradually drops with the development of DR (diabetic retinopathy), therefore the GMFB is applicable to dynamic detection of DR progress; the invention is the first to prove that by interfering GMFB expression in rats of DR, visual function can be protected; and the invention is the first to prove that GMFB mediates retinopathy mechanism, including causing decrease of glutamine synthetase of Muller cell, death of ganglion cells and inducing autophagy of photoreceptor cells.
Owner:TONGJI UNIV

Two-dimensional photoreceptor array, holographic optical information playback device, and holographic optical information recording device

A holographic optical information playback apparatus for playing information that is recorded on a recording medium in a form of interference fringes is provided with a two-dimensional photoreceptor array which receives a two-dimensional array of light spots that is diffracted at the recording medium due to application of reference light onto the medium, and outputs a playback signal including information recorded on the recording medium. The two-dimensional photoreceptor array has a photoreceptor section in which plural photoreceptor cells for detecting the intensities of received lights are arranged so that a photoreceptive area corresponding to the light spot array is formed, and assigns plural photoreceptor cells are assigned to each light spot in the light spot array according to the irradiation position of the light spot array, whereby the light intensity of one light sport is detected using the output signals from the plural photoreceptor cells.
Owner:PANASONIC CORP

Methods for preserving photoreceptor cell viability following retinal detachment

Provided are methods for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a hydrophilic bile acid (e.g., UDCA or TUDCA) to a mammal having an eye with a detached retina. Administration of the hydrophilic bile acid maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid, thereby minimizing the loss of vision or visual acuity, which otherwise may occur as a result of the retinal detachment.
Owner:MASSACHUSETTS EYE & EAR INFARY

Co-culture method of photosensory precursor cells and retinal tissue in vitro

The invention relates to a co-culture method of photosensory precursor cells and retinal tissue in vitro and aims to build a co-culture system for the photosensory precursor cells and denaturation retinal tissue of retina photoreceptor cells. The method comprises the following steps: a photosensory precursor cell layer of an embryonic eye source is prepared; a nerve cell layer of a denatured retina is prepared; the nerve cell layer of the denatured retina is placed on the photosensory precursor cell layer; an epithelial layer of retinochrome is prepared in the lower chamber of a plug-in type tissue culture dish; the co-culture system of the retinal tissue and cells is built in vitro, and the retinal tissue and cells are cultured in an incubator with 5% CO2 at the temperature of 37 DEG C. By adopting the method provided by the invention, the biological characteristics and cellular structure of host cells and transplanted cells, the synaptic contact of the transplanted cells and the host cells, and the chromatin conformation reconstruction of the transplanted cells and the host cells can be observed and detected directly in vitro, and the traces of survival, proliferation, differentiation and functional reconstruction of photosensory precursor cells of a transplanted embryonic eye source can be tracked.
Owner:GENERAL HOSPITAL OF PLA

Glycan binding proteins as therapeutic targets for retinal disorders and treatment methods based thereon

Disclosed are novel methods of treatment for retinal diseases and conditions including age-related macular degeneration, genetic-based retinal degenerations and retinal detachment. A novel glycan binding protein thought to be a cell surface receptor has been discovered in the retina. The retinal glycan binding receptor is shown to play an important role in promoting assembly of outer segment (OS) membranes by the photoreceptor cells of the eye, a process that is essential for vision. Based on the finding that certain sugars can bind with very high affinity to the retinal glycan receptor and stimulate its function, the invention provides novel therapeutic agents for treatment of retinal diseases that are multivalent N-linked glycans. Preferred pharmaceutical compositions in accordance with the present invention comprise active agents having the general formula: (Gal-GlcNAc)n-Man3-GlcNAc2, where n is 1-4. Particularly preferred multivalent glycans are galactosylated, biantennary (NA2), and asialo, galactosylated, triantennary (NA3) oligosaccharides.
Owner:UNIV OF TENNESSEE RES FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products